Biohaven Ltd. (NYSE: BHVN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
13.75
+0.38+2.84%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -15.26 | Insider Own | 8.27% | Shs Outstand | 150.56M | Perf Week | -0.15% |
| Market Cap | 2.07B | Forward P/E | - | EPS next Y | -2.37 | Insider Trans | 0.00% | Shs Float | 123.75M | Perf Month | -14.33% |
| Enterprise Value | 2.00B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 15.63% | Perf Quarter | 35.60% |
| Income | -889.00M | P/S | 10.90 | EPS this Y | 80.41% | Inst Trans | - | Short Ratio | 6.82 | Perf Half Y | 17.02% |
| Sales | 190.00M | P/B | 15.93 | EPS next Y | 20.64% | ROA | -138.87% | Short Interest | 19.35M | Perf YTD | 21.79% |
| Book/sh | 0.86 | P/C | 5.95 | EPS next 5Y | - | ROE | -866.46% | 52W High | 18.57 -25.96% | Perf Year | -6.53% |
| Cash/sh | 2.31 | P/FCF | - | EPS past 3/5Y | - | ROIC | -155.69% | 52W Low | 7.48 83.82% | Perf 3Y | -27.82% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 4.85% 5.96% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 10.54 | EPS Y/Y TTM | -64.44% | Oper. Margin | 0.00% | ATR (14) | 0.87 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.41 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 46.53 | Recom | 2.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.41 | EPS Q/Q | 59.45% | SMA20 | -6.40% | Beta | 1.01 | Target Price | 15.40 |
| Payout | 0.00% | Debt/Eq | 5.37 | Sales Q/Q | - | SMA50 | 1.50% | Rel Volume | 0.84 | Prev Close | 13.37 |
| Employees | 274 | LT Debt/Eq | 5.37 | Earnings | Aug 10 | SMA200 | 19.05% | Avg Volume | 2.89M | Price | 13.75 |
| IPO Date | Sep 23, 2022 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -5.86% - | Net Debt/EBITDA | -0.02 | Volume | 2,414,540 | Change | 2.84% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-29-26 | Reiterated | Needham | $11 | |
| Jun-29-26 | Downgrade | B of A Securities | Neutral → Underperform | |
| May-13-26 | Reiterated | Morgan Stanley | Overweight | $26 → $18 |
| Mar-04-26 | Reiterated | HC Wainwright & Co. | Neutral | $11 → $10 |
| Mar-03-26 | Reiterated | Leerink Partners | Outperform | $15 |
| Feb-05-26 | Initiated | Goldman Sachs | Buy | $23 |
| Jan-21-26 | Upgrade | RBC Capital | Sector Perform → Outperform | $22 |
| Dec-03-25 | Downgrade | HC Wainwright & Co. | Buy → Neutral | $11 |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral | $11 |
| Nov-18-25 | Reiterated | Morgan Stanley | Overweight | $26 |
Latest News
Jul-27-26
Jul-27-2607:08AM
07:00AM
Jul-20-26
Jul-20-2607:30AM
Jul-19-26
Jul-19-2610:51PM
Jul-13-26
Jul-09-26
Jun-30-26
Jun-30-2607:31AM
07:30AM
Jun-29-26
08:11AM
07:30AM
Jun-23-26
Jun-18-26
Jun-18-2603:28PM
Jun-12-26
Company
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 190 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 44 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 145 | -4 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 572 | 106 | 89 | 63 | 131 | 37 | 16 | 134 | |
| Research and Development | 253 | 635 | 796 | 373 | 437 | 181 | 98 | 345 | |
| Other Operating Expense | 62 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | |
| Operating Income | -742 | -745 | -885 | -436 | -568 | -219 | -115 | -479 | |
| Interest Expense | -7 | 0 | 0 | 0 | 0 | 0 | 0 | -13 | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 231 | 8 | 39 | 27 | -2 | 6 | -4 | -62 | |
| Net Income Before Taxes | -503 | -737 | -846 | -410 | -570 | -212 | -119 | -528 | |
| Income Taxes | 17 | 1 | 1 | -1 | 0 | 1 | 0 | 0 | |
| Consolidated Net Income | -889 | -739 | -846 | -408 | -570 | -214 | -119 | -529 | |
| Net Income From Continuing Operations | -521 | -739 | -846 | -408 | -570 | -214 | -119 | -529 | |
| Net Income | -889 | -739 | -846 | -408 | -570 | -214 | -119 | -529 | |
| EPS (Recurring) | -15.26 | -6.86 | -9.28 | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | |
| EPS (Basic, Before Extraordinaries) | -15.26 | -6.86 | -9.28 | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | |
| EPS (Diluted) | -15.26 | -6.86 | -9.28 | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | |
| EBITDA | -481 | -727 | -838 | -403 | -568 | -211 | -114 | -479 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.70 | — | — | — | — | — | — | — | |
| Gross Margin | 76.32 | — | — | — | — | — | — | — | |
| Operating Margin | -390.53 | — | — | — | — | — | — | — | |
| Net Margin | -467.89 | — | — | — | — | — | — | — | |
| Shares Outstanding | 65 | 108 | 91 | 71 | 45 | 36 | 36 | 48 | |
| Market Capitalization | 894 | 1,219 | 3,399 | 3,039 | 625 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| CHILDS JOHN W | Director | Mar 04 '25 | Buy | 30.45 | 61,100 | 1,860,354 | 2,323,971 | Mar 09 |
| Clark George C. | VP, Chief Accounting Officer | Jan 05 '26 | Option Exercise | 0.00 | 2,500 | 0 | 68,095 | Jan 07 |
| Coric Vlad | Chief Executive Officer | Jan 05 '26 | Option Exercise | 0.00 | 14,250 | 0 | 1,811,398 | Jan 07 |
| Gentile Kimberly | SVP, Clinical Operations | Jan 05 '26 | Option Exercise | 0.00 | 3,750 | 0 | 101,513 | Jan 07 |
| Buten Matthew | Chief Financial Officer | Jan 05 '26 | Option Exercise | 0.00 | 4,250 | 0 | 198,246 | Jan 07 |
| Car Bruce | Chief Scientific Officer | Jan 05 '26 | Option Exercise | 0.00 | 4,750 | 0 | 10,096 | Jan 07 |
| Clark George C. | VP, Chief Accounting Officer | Nov 17 '25 | Buy | 8.52 | 17,000 | 144,770 | 20,000 | Nov 18 |
| Bailey Gregory | Director | Nov 13 '25 | Buy | 7.50 | 400,000 | 3,000,000 | 2,020,071 | Nov 17 |
| CHILDS JOHN W | Director | Nov 13 '25 | Buy | 7.50 | 3,333,333 | 24,999,998 | 5,653,904 | Nov 17 |
| Coric Vlad | Chief Executive Officer | Nov 13 '25 | Buy | 7.50 | 666,666 | 4,999,996 | 1,195,275 | Nov 17 |
| CHILDS JOHN W | Director | Apr 22 '24 | Buy | 41.00 | 268,291 | 10,999,931 | 4,096,512 | Mar 05 |
| Car Bruce | Chief Scientific Officer | Jan 05 '25 | Option Exercise | 0.00 | 4,750 | 0 | 7,133 | Jan 07 |
| Gentile Kimberly | SVP, Clinical Operations | Jan 05 '25 | Option Exercise | 0.00 | 3,750 | 0 | 99,719 | Jan 07 |
| Clark George C. | VP, Chief Accounting Officer | Jan 05 '25 | Option Exercise | 0.00 | 2,500 | 0 | 66,168 | Jan 07 |
| Buten Matthew | Chief Financial Officer | Jan 05 '25 | Option Exercise | 0.00 | 4,250 | 0 | 196,013 | Jan 07 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.